Modern microscopy has confirmed an important but easily overstated point about Ayurvedic bhasma: some preparations contain nanometre-scale crystallites, while the powder actually swallowed may contain much larger agglomerates. In a 2011 study of two Swarna Bhasma batches, X-ray diffraction estimated gold crystallites at 28–35 nm, but particle-size measurements found mean diameters in the hundreds of nanometres. A 2017 study found crystallites of about 60 nm assembled into irregular aggregates with a mean hydrodynamic diameter of about 4.7 µm. These findings support materials-science study, but they do not prove that every bhasma is a uniform nanoparticle medicine or that nanoscale size establishes clinical efficacy.

What Is Bhasma? The Classical Pharmaceutical Framework

Bhasma is a fine calcined preparation made from specified metals, minerals, shells or other substances through formula-specific procedures described in Rasa Shastra literature and official Ayurvedic formularies. There is no universal recipe; the sequence, liquids, auxiliary substances, heat pattern and endpoint tests depend on the material and cited method.

  1. Shodhana: preliminary processing that may involve heating and quenching, boiling, washing, grinding or treatment with prescribed liquids. Calling it removal of all “toxins” is too broad; it is material-specific purification and pharmaceutical pretreatment.
  2. Bhavana: wet grinding or levigation with a specified juice, decoction or other liquid. It mixes ingredients, reduces coarse particles and prepares the mass for further processing.
  3. Marana and Putapaka: repeated calcination according to the chosen method, often after pellets are enclosed in an earthen sharava-samputa. Modern studies may use a muffle furnace to reproduce a temperature profile. Depending on ingredients and atmosphere, the product may contain elemental metal, oxides, sulfides or mixed phases; the process is not uniformly a reduction reaction.
  4. Amritikarana, where prescribed: some Tamra or Lauha methods include an additional finishing process. It is not mandatory for every bhasma, and evidence does not support calling it a universal organic coating or proven tissue-targeting step.

Classical endpoint examinations include nishchandratva (absence of visible metallic lustre), rekhapurnatva (fineness sufficient to enter finger lines), varitaratva (floating on still water in the prescribed test) and, where relevant, apunarbhava, which examines resistance to reversion toward the original metal. These process checks do not replace modern identity, composition, contamination, particle-distribution and toxicology testing.

What Microscopy and Diffraction Actually Show

Published measurements differ because studies examine different products and techniques. XRD crystallite size, TEM primary-particle size, SEM aggregate size and DLS hydrodynamic diameter are not equivalent. A powder can contain nanoscale crystallites while behaving as micron-scale aggregates in liquid.

Preparation Verified finding Qualification
Swarna Bhasma Gold crystallites of 28–35 nm in two batches; measured particle diameters were much larger. In-vitro compatibility does not establish efficacy.
Swarna Bhasma A separate report described globular gold-containing particles averaging about 56–57 nm. Not generalizable to all products.
Incinerated gold About 60 nm crystallites formed aggregates averaging about 4.7 µm by DLS. Cell-culture, preparation-specific evidence.
Laboratory Swarna Bhasma FE-TEM reported highly crystalline gold structures containing roughly 5–20 nm particles. Other studies report micron-scale powder particles.
Rajata Bhasma One sample contained crystalline silver in aggregates around 170–210 nm. Does not support a universal 2–3 nm value.
Tamra Bhasma One standardized preparation was mainly cupric sulfide, with 10% below 2 µm. Chemistry depended on that method.

The defensible conclusion is that bhasma processing can produce complex micro- and nanostructured materials. It is inaccurate to assign one fixed particle size to each named bhasma. Batch variation is a major research and quality-control issue.

Particle Size, Absorption and Bioavailability

Smaller particles can have greater surface area, but absorption depends on aggregation, dissolution, chemical species, protein binding, surface charge, dose, food, vehicle and intestinal physiology. General nanoparticle transport mechanisms cannot be automatically assigned to a bhasma without product-specific experiments.

A small 2018 human pilot study measured trace gold in blood after single sublingual or oral Swarna Bhasma doses and reported different concentration-time patterns with different routes and accompanying media. It did not establish long-term pharmacokinetics, tissue distribution, clinical benefit or safety in disease. In a 2017 cell-culture study, smaller incinerated-gold particles appeared to enter cells through clathrin-dependent endocytosis and larger aggregates through macropinocytosis; oral intestinal passage and organism-level effects remained unresolved.

Lauha Bhasma is traditionally used in iron-containing Ayurvedic formulations, and modern work has characterized iron-oxide phases, but comparative clinical bioavailability and gastrointestinal tolerability require proper human trials.

Herbal Processing and Surface Chemistry

Plant juices, decoctions, oils, milk products and other media can participate in grinding, complexation, oxidation, sulfide formation and transfer of trace constituents. Analytical studies have detected carbon and multiple elements in some samples. This supports research on process-derived surface chemistry.

Terms such as “functionalization,” “zeta-potential control” and “organ targeting” should be used only when measured for the exact preparation. No reliable human evidence shows that a processing liquid directs bhasma particles selectively to the heart, kidney, brain or another organ. Classical indications and modern nanoparticle-targeting mechanisms are different categories of evidence.

Specific Preparations: Current Evidence

Each preparation must be judged as a distinct pharmaceutical material. Traditional indications can guide research, but they do not substitute for verified trials, standardized composition or contemporary diagnosis.

Swarna Bhasma

Swarna Bhasma is a calcined gold preparation used in later Rasa Shastra and Ayurvedic pharmaceutical practice. The 2011 in-vitro study found negligible hemolysis, aggregation, platelet activation and cytotoxicity for its tested batches; the 2017 study found no toxicity in two cultured human cell lines under its conditions. These results are assay- and product-specific.

A randomized study of Swarna Bhasma, honey and ghee in healthy infants reported no significant between-group advantage in IgG over honey and ghee alone during the study period. It is not evidence that Swarna preparations function as vaccines or prevent infection. Pediatric use requires specialist oversight and reliable product quality.

Lauha Bhasma

Lauha Bhasma is an iron-based preparation produced by methods that may include shodhana, Triphala processing, calcination and amritikarana. Structural studies describe iron-oxide phases rather than one universally fixed compound. A 2016 rat study found no major toxicity at therapeutic-equivalent and five-times levels, but biochemical and histopathological alterations appeared at the highest repeated dose. Animal toxicology neither determines an individual dose nor proves superiority to standard oral iron.

Pravala Pishti

Pravala Pishti is a cold-processed coral preparation, not a bhasma produced by repeated incineration. It is made through fine grinding and levigation according to the selected formulary. It should not replace clinically indicated calcium or osteoporosis treatment.

The Safety Question

Safety cannot be inferred from the words “classical,” “purified,” “nano” or “GMP.” Case reports and surveys have documented lead, mercury or arsenic exposure from some Ayurvedic products, including severe liver injury and systemic toxicity. Conversely, controlled animal studies of particular, characterized bhasmas sometimes report acceptable findings at specified doses and harm at higher doses. Both realities must be acknowledged.

Traditional tests help monitor manufacture, while modern evaluation should include authenticated raw materials, validated process records, chemical speciation, assay of intended ingredients, limits for unintended contaminants, microbial quality and batch-specific certificates of analysis. India’s Drugs Rules place Ayurvedic, Siddha and Unani manufacturing under Schedule T GMP requirements intended to ensure authentic raw materials, prescribed processes, quality control and acceptable finished-product quality. GMP is important, but it does not guarantee clinical efficacy or zero risk.

Disclaimer: Never self-prescribe a bhasma or use an unlabelled metallic preparation. Use only a legally manufactured, batch-tested product prescribed by a qualified Ayurvedic physician experienced in Rasa Shastra, and tell your healthcare provider about every medicine and supplement you take. Extra caution and medical review are essential in pregnancy, childhood, kidney or liver disease, anemia of uncertain cause, and when medicines may affect renal, hepatic or blood function. Suspected adverse effects require prompt medical assessment and, when appropriate, blood metal testing.

Where Research Should Go Next

Research should establish reproducible manufacturing protocols, distinguish primary particles from aggregates, identify chemical species and surface constituents, measure dissolution and bioaccessibility, and compare batches from multiple manufacturers. Pharmacokinetic studies must track absorption, distribution and elimination rather than relying on one early blood measurement.

Clinical studies should use authenticated products, adequate controls, prespecified outcomes, transparent adverse-event reporting and independent replication. Until then, microscopy shows that classical processing can create complex materials; it does not prove rejuvenation, cognitive enhancement, organ targeting or superior bioavailability. Rasa Shastra is represented more accurately when analytical findings, classical doctrine and clinical claims remain clearly separated.

References

  1. Blood compatibility studies of Swarna bhasma (gold bhasma), an Ayurvedic drug (2011), PubMed
  2. Nanogoldpharmaceutics (2007)
  3. Comparative study on cellular entry of incinerated ancient gold particles (Swarna Bhasma) and chemically synthesized gold particles (2017)
  4. Nanostructured gold in ancient Ayurvedic calcined drug ‘swarnabhasma’ (2021)
  5. Characterization of Rajath Bhasma and Evaluation of Its Toxicity in Zebrafish Embryos and Its Antimicrobial Activity (2020), PubMed
  6. Standard manufacturing procedure of Tamra Bhasma (2012)
  7. Assessment of bioavailability of gold bhasma in human participants – A pilot study (2018), PubMed
  8. Immunomodulatory activity of Swarna Prashana (oral administration of gold as electuary) in infants – A randomized controlled clinical trial (2019), PubMed Central
  9. Toxicity study of Lauha Bhasma (calcined iron) in albino rats (2016), PubMed
  10. Ayurveda metallic-mineral ‘Bhasma’-associated severe liver injury (2018), PubMed Central
  11. Toxic metals in ayurvedic preparations from a public health lead poisoning cluster investigation (2017), PubMed Central
  12. CDSCO (India)

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.

Tags: Bhasma bioavailability Mineral Medicines Nano-Particles Nanotechnology Rasa Shastra research